Cramer Remix: The sky is the limit for this stock

Cramer: Sky's the limit for this stock
Cramer: Sky's the limit for this stock   

Another manic merger Monday goes in the books.

One of the recent mergers that caught Jim Cramer's eye was with Publicis, the large French advertising firm, and its intentions to purchase Sapient, a consulting firm.

He realized this merger is exactly what the stock market needs right now: Storytelling. The deal between Publicis and Sapient will ultimately make Publicis more relevant in the digital world.

That's the exact reason why stocks like Google, Facebook and Twitter have remained undervalued, despite various missteps in the market rally last week.

In his research on Sapient, Cramer came across a speech given by actor Kevin Spacey that he considered brilliant. Spacey reiterated that there is an explosion of storytelling right now. In the stock market, people want to be data generators rather than consumers. Meaning, they want to create stories.

"Maybe all three companies should just hire Kevin Spacey," said Cramer. He's clearly a guy who knows how to tell a story, and that's exactly what people want—a tangible connection, with no grand schemes that may or may not make money one day.

Read MoreCramer: Google, Facebook & Twitter should hire Kevin Spacey

Kevin Spacey
Getty Images
Kevin Spacey

Waste Management is one of those stocks that Cramer has liked forever. It is the largest waste disposal company in America, with 269 landfills and 279 transfer stations. This stock also features a robust 3.1 percent dividend, which is much higher than the 10-year treasury is yielding these days.

Though this stock has been sleepy for the year, Cramer sat down with Waste Management CEO David Steiner to find out where the company is headed. Could one man's trash be another man's treasure?

"We're always going to be a more price dominated company than volume. If you lower the price of trash, people don't create more trash. Trash is not a consumer product, as opposed to if you lower the price of flat screen TV's, people buy more flat screen TV's," said Steiner.

Though this type of stock tends to rally slower than a turtle, Cramer thinks there could much more upside to Waste Management.

One stock that is certainly not considered sleepy, is Alibaba. As the market braces for it to report earnings for the first time since the launch of its massive IPO, Cramer thinks the stars have aligned and investors will be willing to pay big bucks for it.

"Alibaba is Amazon on steroids, except unlike Amazon, it's extremely profitable. Therefore, the sky might be the limit for what any Amazon holder might be willing to pay for Alibaba in comparison," said the "Mad Money" host.

Cramer knows if managers are already foaming at the mouth and ready to pay high price when they don't even know what the earnings will be, this stock is only just beginning to head higher.

Read MoreCramer: Alibaba hasn't even scratched the surface

Jim Cramer Mad Money
Source: CNBC

Speaking of manic Monday, in November 2013 Kimberly-Clark, known for products such as Kleenex, announced that it would spin off its health care division into a separate company called Halyard Health.

No need to grab a tissue or eat a tub of ice cream to mourn the breakup on this one. Cramer actually thinks this made a ton of sense.

Additionally, with contagious diseases such as Ebola fresh on the minds of investors, this spin-off came at a good time. Halyard is expected to generate $1.7 billion in annual sales, and is the maker of surgical and infection prevention products for the operating room.

Could the Ebola epidemic really be boosting this stock on its first day of trading? Cramer spoke with Halyard Health CEO Robert Abernathy to find out if it is a distributor within Ebola markets and whether he has seen an increase due to the disease.

"Yes, we are in those markets," Abernathy said. "We manufacture products for infection control that are part of the [Centers for Disease Control] protocol for stopping the advancement of the disease. We are growing a little bit, but it's hard to tell whether it is based on Ebola, or just a normal build up of business due to cold and flu season."

The company's main focus within the first year will be to establish itself independent of Kimberly-Clark, and the second year will be to better utilize their cash surplus to make strategic acquisitions to expand in its markets.

Cramer continued to speculate stocks headed higher, by addressing a few caller favorites in the Lightning Round:

Sysco: "I want that deal closed, it didn't. I'm losing a little heart for SYY. It's just not coming together for me like I thought it would."

Omega Healthcare: "I think that Ventas has got more game, it's got more growth."

Read MoreLightning Round: Celgene, Sysco & more